The rise of SARS-CoV-2 variants with specific mutations has raised serious concerns, such as that these mutations will affect virus sensitivity to antibodies and the potential exists that the current vaccines might be ineffective. This has been proven in some cases where specific variants are not neutralised by antibodies produced against the vaccine strain, since they do not produce effective cross-neutralising antibodies. This again prompts the importance of SA institutions to play a part in developing vaccines and diagnostic assays that incorporate the new variants, including B.1.351, which has been shown to produce cross-neutralising antibodies with the potential to neutralise other variants and limit infections.
My project would aim to express SARS-CoV-2 and the South African B.1.351 variant proteins, such as the spike and nucleocapsid proteins in the yeast Yarrowia lipolytica. Variations of the spike protein will also be examined to optimise expression in this system. The expression will be carried out using expression vectors that allow for the surface display, internalisation, and secretion of these proteins using the patented Yarrowia lipolytica expression system. Upon expression, various protein purification strategies will have to be explored for downstream applications, such as potential subunit vaccine development and diagnostic assays.